A novel immunotherapy could lead to a brain cancer breakthrough after showing promising results against glioblastoma, the most aggressive and deadliest form, researchers have said.
Patients diagnosed with this condition typically survive for only 12 to 18 months. Experts at King’s College London and McMaster University in Canada have conducted laboratory work suggesting CAR-T cell therapy could be a treatment. This therapy teaches the body’s immune system to recognise and attack cancerous cells, having already shown dramatic results in other cancer patients. Some CAR-T treatments are now routinely available on the NHS.
